Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

[1]  D. Ding,et al.  Regulation of Hepatic Metabolism and Cell Growth by the ATF/CREB Family of Transcription Factors , 2021, Diabetes.

[2]  D. Xirodimas,et al.  Proteome-wide identification of NEDD8 modification sites reveals distinct proteomes for canonical and atypical NEDDylation. , 2021, Cell reports.

[3]  Jieun Seo,et al.  Neddylation of sterol regulatory element-binding protein 1c is a potential therapeutic target for nonalcoholic fatty liver treatment , 2020, Cell Death & Disease.

[4]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[5]  C. Hoogenraad,et al.  Global site-specific neddylation profiling reveals that NEDDylated cofilin regulates actin dynamics , 2020, Nature Structural & Molecular Biology.

[6]  D. Prati,et al.  Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker , 2020, Gut.

[7]  Xueying Zhang,et al.  Hepatic neddylation targets and stabilizes electron transfer flavoproteins to facilitate fatty acid β-oxidation , 2020, Proceedings of the National Academy of Sciences.

[8]  A. Sanyal,et al.  Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease. , 2020, Cell metabolism.

[9]  F. Lopitz-Otsoa,et al.  Ubiquitin-Like Post-Translational Modifications (Ubl-PTMs): Small Peptides with Huge Impact in Liver Fibrosis , 2019, Cells.

[10]  N. Webster,et al.  Degradation of splicing factor SRSF3 contributes to progressive liver disease. , 2019, The Journal of clinical investigation.

[11]  A. Gartner,et al.  The Balance between Mono- and NEDD8-Chains Controlled by NEDP1 upon DNA Damage Is a Regulatory Module of the HSP70 ATPase Activity , 2019, Cell reports.

[12]  L. Henry,et al.  Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States , 2019, Hepatology communications.

[13]  F. Tacke,et al.  Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis , 2019, Hepatology.

[14]  Ying E. Zhang,et al.  Non-proteolytic ubiquitin modification of PPARγ by Smurf1 protects the liver from steatosis , 2018, PLoS biology.

[15]  G. Shulman,et al.  Acetyl‐CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents , 2018, Hepatology.

[16]  S. Pelusi,et al.  Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[17]  F. Liu,et al.  DEP domain–containing mTOR–interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute‐on‐chronic liver injury in alcoholic liver disease , 2018, Hepatology.

[18]  F. Lopitz-Otsoa,et al.  Neddylation, a novel paradigm in liver cancer. , 2018, Translational gastroenterology and hepatology.

[19]  Shelly C. Lu,et al.  The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury , 2017, Nature Communications.

[20]  Zhi‐Gang She,et al.  USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity , 2017, Hepatology.

[21]  Shelly C. Lu,et al.  Deregulated neddylation in liver fibrosis , 2017, Hepatology.

[22]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[23]  T. T. Le,et al.  Molecular classification of fatty liver by high‐throughput profiling of protein post‐translational modifications , 2016, The Journal of pathology.

[24]  Ismael Torres,et al.  The MLN4924 inhibitor exerts a neuroprotective effect against oxidative stress injury via Nrf2 protein accumulation , 2016, Redox biology.

[25]  S. Awasthi,et al.  Antioxidant role of glutathione S-transferases: 4-Hydroxynonenal, a key molecule in stress-mediated signaling. , 2015, Toxicology and applied pharmacology.

[26]  Alexandre Caron,et al.  The Roles of mTOR Complexes in Lipid Metabolism. , 2015, Annual review of nutrition.

[27]  Ying Zhang,et al.  Nrf2 regulates ROS production by mitochondria and NADPH oxidase , 2015, Biochimica et biophysica acta.

[28]  Y. Harazono,et al.  Gp78, an E3 Ubiquitin Ligase Acts as a Gatekeeper Suppressing Nonalcoholic Steatohepatitis (NASH) and Liver Cancer , 2015, PloS one.

[29]  Shelly C. Lu,et al.  Stabilization of LKB1 and Akt by neddylation regulates energy metabolism in liver cancer , 2014, Oncotarget.

[30]  S. Ricoult,et al.  The multifaceted role of mTORC1 in the control of lipid metabolism , 2013, EMBO reports.

[31]  H. El‐Serag,et al.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  Y. Sun,et al.  Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis , 2012, Cell Death and Disease.

[33]  T. Slaga,et al.  Inhibition of Neddylation Represses Lipopolysaccharide-induced Proinflammatory Cytokine Production in Macrophage Cells , 2012, The Journal of Biological Chemistry.

[34]  Donna D. Zhang,et al.  Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. , 2010, Antioxidants & redox signaling.

[35]  C. Ahn,et al.  Suppression of NF-kappaB signaling by KEAP1 regulation of IKKbeta activity through autophagic degradation and inhibition of phosphorylation. , 2010, Cellular signalling.

[36]  H. Tilg,et al.  Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.

[37]  David M. Sabatini,et al.  An Emerging Role of mTOR in Lipid Biosynthesis , 2009, Current Biology.

[38]  Amanda Doucette,et al.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer , 2009, Nature.

[39]  Shelly C. Lu.  Regulation of glutathione synthesis. , 2009, Molecular aspects of medicine.

[40]  Daniel C. Scott,et al.  Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of Conjugation , 2008, Cell.

[41]  G. Perdomo,et al.  The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes. , 2007, Metabolism: clinical and experimental.

[42]  H. Otu,et al.  A high-fat, ketogenic diet induces a unique metabolic state in mice. , 2007, American journal of physiology. Endocrinology and metabolism.

[43]  R. E. Pitas,et al.  Mice fed a lipogenic methionine-choline-deficient diet develop hypermetabolism coincident with hepatic suppression of SCD-1 s⃞ Published, JLR Papers in Press, July 8, 2006. , 2006, Journal of Lipid Research.

[44]  Paul J Thornalley,et al.  Transcription factor Nrf2 is essential for induction of NAD(P)H:quinone oxidoreductase 1, glutathione S-transferases, and glutamate cysteine ligase by broccoli seeds and isothiocyanates. , 2004, The Journal of nutrition.

[45]  K. Itoh,et al.  Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. , 2003, The Biochemical journal.

[46]  C. Kellendonk,et al.  Hepatocyte‐specific expression of Cre recombinase , 2000, Genesis.

[47]  L. Henry,et al.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018, Nature Reviews Gastroenterology & Hepatology.